Topics

Glioblastoma | Treatment | Immunotherapy | Viruses

Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Viruses

*Rossmeisl JH, King JN, Robertson JL, Weger-Lucarelli J, Elankumaran S.
Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors.
Cancers (Basel). 2024 Jan 29;16(3):564. doi: 10.3390/cancers16030564. PMID: 38339315. Interventional animal study. ˍ

Calderón-Peláez MA, Maradei Anaya SJ, Bedoya-Rodríguez IJ, González-Ipuz KG, Vera-Palacios D, Buitrago IV, Castellanos JE, Velandia-Romero ML.
Zika Virus: A Neurotropic Warrior against High-Grade Gliomas-Unveiling Its Potential for Oncolytic Virotherapy.
Viruses. 2024 Apr 3;16(4):561. doi: 10.3390/v16040561. PMID: 38675903;. Review. ˍ

Keshavarz M, Dianat-Moghadam H, Ghorbanhosseini SS, Sarshari B.
Oncolytic virotherapy improves immunotherapies targeting cancer stemness in glioblastoma.
Biochim Biophys Acta Gen Subj. 2024 Jun 18;1868(9):130662. doi: 10.1016/j.bbagen.2024.130662. PMID: 38901497. Review˰ ˍ

Stergiopoulos GM, Concilio SC, Galanis E.
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.
Curr Treat Options Oncol. 2024 Jun 19. doi: 10.1007/s11864-024-01211-6. PMID: 38896326. Review˰ ˍ

Kim S, Jung BK, Kim J, Jeon JH, Kim M, Jang SH, Kim CS, Jang H.
Anticancer effect of the oncolytic Newcastle disease virus harboring the PTEN gene on glioblastoma.
Oncol Lett. 2024 Oct 16;29(1):6. doi: 10.3892/ol.2024.14752. PMID: 39492938. Laboratory investigation. ˍ

Gunasegaran B, Ashley CL, Marsh-Wakefield F, Guillemin GJ, Heng B.
Viruses in glioblastoma: an update on evidence and clinical trials.
BJC Rep. 2024 Apr 19;2(1):33. doi: 10.1038/s44276-024-00051-z. PMID: 39516641. Review. ˍ

Meléndez-Vázquez NM, Gomez-Manzano C, Godoy-Vitorino F.
Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas.
Viruses. 2024 Nov 14;16(11):1775. doi: 10.3390/v16111775. PMID: 39599889. Review. ˍ

Coates K, Nibbs RJ, Fraser AR.
Going viral: targeting glioblastoma using oncolytic viruses.
Immunother Adv. 2025 Jul 25;5(1):ltaf024. doi: 10.1093/immadv/ltaf024. PMID: 40717958. Review. ˍ

Alomari O, Eyvazova H, Güney B, Al Juhmani R, Odabasi H, Al-Rawabdeh L, Mokresh ME, Erginoglu U, Keles A, Baskaya MK.
Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives.
Cancers (Basel). 2025 Aug 1;17(15):2550. doi: 10.3390/cancers17152550. PMID: 40805247. Review. ˍ

Daftari M, Ramsoomair CK, Aaronson D, Seetharam D, Andreae EA, Wright L, Han S, Chandar J, Lu V, Govindarajan V, Ivan ME, Komotar RJ, de la Fuente M, Shah AH.
Synergistic Treatment with Antiretrovirals and Laser Interstitial Thermal ThErapy (STARLITE) for unresectable glioblastoma: A phase 1 study protocol.
PLoS One. 2025 Aug 28;20(8):e0328204. doi: 10.1371/journal.pone.0328204. PMID: 40875628. Interventional study protocol. ˍ

Zhang X, Li Y, Liu N, Zhang Y, Yang N, Zhou L.
Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles.
Int Immunopharmacol. 2025 Sep 15;166:115547. doi: 10.1016/j.intimp.2025.115547. PMID: 40957170. Review˰ ˍ

Nizamutdinov D, Sentmanat A, Tong J, Qi X, Pan Y, Qi D, Wu E, Huang JH.
The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.
Cancers (Basel). 2025 Oct 28;17(21):3465. doi: 10.3390/cancers17213465. PMID: 41228258. Review. ˍ

Söderberg-Naucler C, Pantalone MR, Stragliotto G, Bartek J.
Does human cytomegalovirus provide a novel therapeutic target for patients with glioblastoma?
Philos Trans R Soc Lond B Biol Sci. 2025 Nov 6;380(1938):20240403. doi: 10.1098/rstb.2024.0403. PMID: 41194660. Review. ˍ

Liu J, Wang Y, Su S, Cheng G, Zhao H, Sun J, Sun G, Li F, Hui R, Liu M, Wu L, Wu D, Yang F, Dang Y, Hei J, Li Y, Gao Z, Wang B, Bai Y, Lv W, Zhang J.
Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions.
Cancers (Basel). 2025 Dec 10;17(24):3948. doi: 10.3390/cancers17243948. PMID: 41463198. Review. ˍ

Flores T, Delpierre E, Male G, Gourin C, Hantz S, Damour A, Ligat G.
Targeting Human Cytomegalovirus as a Novel Approach for Glioblastoma Treatment.
Pathogens. 2025 Dec 16;14(12):1291. doi: 10.3390/pathogens14121291. PMID: 41471245. Review. ˍ

Zeng W, Wang P, Fang S, Ge S, Jia W, Peng S, Wang M, Qin X, Zhang W, Gao J, Su X, Yuan G, Wu J, Liu Y, Wang Y, Lu H, Mu R, Wu F, Chang Q, Jin G, Meng F, Zhang J, Liu F.
ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: a single-arm, phase 1/2 study.
Neuro Oncol. 2026 Jan 12:noag005. doi: 10.1093/neuonc/noag005. PMID: 41527280. Interventional study. ˍ

Ene CI, Singh S, Venkataraman T, Phillips LM, Long JP, Singh D, Tran ND, Tufaro F, Anand PJ, Navin N, Prabhu S, Weinberg JS, Larman HB, Gomez-Manzano C, Fueyo J, Lang FF.
Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET).
Clin Cancer Res. 2026 Jan 29. doi: 10.1158/1078-0432.CCR-25-3566. PMID: 41609523. Interventional study˰ ˍ

Meylan M, Tian Y, Wu L, Ling AL, Kovarsky D, Barlow GL, Nguyen LD, Pyrdol J, Marx S, Westphal L, Michel J, Gonzalez Castro LN, Dumont S, Santos A, Tirosh I, Suvà ML, Chiocca EA, Wucherpfennig KW.
Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial.
Cell. 2026 Feb 11;189(5):1287-1304.e18. doi: 10.1016/j.cell.2025.12.055. PMID: 41679299. Interventional study. ˍ